https://scholars.lib.ntu.edu.tw/handle/123456789/473821
標題: | EGFR and p53 status of pulmonary pleomorphic carcinoma: Implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy | 作者: | YIH-LEONG CHANG CHEN-TU WU JIN-YUAN SHIH Lee Y.-C. |
公開日期: | 2011 | 卷: | 18 | 期: | 10 | 起(迄)頁: | 2952-2960 | 來源出版物: | Annals of Surgical Oncology | 摘要: | Background: Pleomorphic carcinomas of the lung are uncommon malignant tumors composed of carcinomatous and sarcomatous components and are distinguished from other non-small-cell lung carcinomas by a more aggressive clinical course with early distant metastases and far worse survival. Epidermal growth factor receptor (EGFR) and p53 are common genes involved in the pathogenesis of non-small-cell lung carcinomas, but their roles in pleomorphic carcinomas are unclear. The potential clinical activity of EGFR-targeted therapy is also unknown. Methods: A total of 42 pleomorphic carcinomas were identified to investigate somatic mutations of EGFR and p53. Genomic DNA was extracted from microdissected cells of paraffin-embedded tumor tissues. Somatic mutations in EGFR (exons 18-21) and p53 (exons 5-8) were examined. Results: EGFR mutations were detected in 10 of 42 cases. Five of these patients had point mutations in exon 21 majorly with L858R; this mutation was found in both adenocarcinomatous and sarcomatous components in 1 case. The other 5 cases harbored 4 deletions and 1 mutation in exon 19. p53 mutations were found in 12 patients. Notably, identical mutation was observed in carcinomatous and sarcomatous components in 3 patients, and this finding strongly supported the theory of monoclonal histogenesis. Conclusions: The occurrence (23.8%) of EGFR mutations, including the exons 19 and 21 mutations observed frequently in our series, suggests that the patients with inoperable pleomorphic carcinomas are likely to benefit from treatment with EGFR tyrosine kinase inhibitors. ? 2011 Society of Surgical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052696734&doi=10.1245%2fs10434-011-1621-7&partnerID=40&md5=95feff420d5057e227cf3b733f61ae74 https://scholars.lib.ntu.edu.tw/handle/123456789/473821 |
ISSN: | 1068-9265 | DOI: | 10.1245/s10434-011-1621-7 | SDG/關鍵字: | epidermal growth factor receptor; genomic DNA; paraffin; protein p53; protein tyrosine kinase inhibitor; adult; aged; article; cancer survival; clinical article; correlation analysis; exon; female; gene; gene amplification; gene deletion; histogenesis; human; human tissue; kras gene; lung carcinoma; lymph node metastasis; male; microdissection; point mutation; protein function; pulmonary pleomorphic carcinoma; sex difference; smoking habit; somatic mutation; tumor volume; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cohort Studies; DNA, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; ras Proteins; Receptor, Epidermal Growth Factor; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。